CY1109079T1 - Συνθεσεις που περιλαμβανουν μονταφινιλη για την θεραπεια διαταραχης ελλειψης προσοχης υπερδραστικοτητας - Google Patents
Συνθεσεις που περιλαμβανουν μονταφινιλη για την θεραπεια διαταραχης ελλειψης προσοχης υπερδραστικοτηταςInfo
- Publication number
- CY1109079T1 CY1109079T1 CY20081101486T CY081101486T CY1109079T1 CY 1109079 T1 CY1109079 T1 CY 1109079T1 CY 20081101486 T CY20081101486 T CY 20081101486T CY 081101486 T CY081101486 T CY 081101486T CY 1109079 T1 CY1109079 T1 CY 1109079T1
- Authority
- CY
- Cyprus
- Prior art keywords
- montafinili
- hyperractivity
- treatment
- compositions including
- modafinil
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Η μονταφινίλη είναι αποτελεσματική στη βελτίωση συμπτωμάτων διαταραχής έλλειψης προσοχής υπερδραστικότητας και συμπτωμάτων κόπωσης σκλήρυνσης κατά πλάκας. Η χορήγηση μονταφινίλης δείχνεται επίσης ότι ενεργοποιεί τους κονδυλοθηλοειδείς νευρώνες του οπίσθιου υποθαλάμου και δεικνύει έτσι δραστικότητα σε μια περιοχή του εγκεφάλου που συνδυάζεται με κανονικές λειτουργίες αγρυπνίας.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14961299P | 1999-08-16 | 1999-08-16 | |
US09/638,353 US6346548B1 (en) | 1999-08-16 | 2000-08-15 | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
EP00954081A EP1253918B1 (en) | 1999-08-16 | 2000-08-16 | Compositions comprising modafinil for the treatment of attention deficit hyperactivity disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109079T1 true CY1109079T1 (el) | 2014-07-02 |
Family
ID=26846889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081101486T CY1109079T1 (el) | 1999-08-16 | 2008-12-22 | Συνθεσεις που περιλαμβανουν μονταφινιλη για την θεραπεια διαταραχης ελλειψης προσοχης υπερδραστικοτητας |
Country Status (20)
Country | Link |
---|---|
US (3) | US6346548B1 (el) |
EP (1) | EP1253918B1 (el) |
JP (1) | JP5542291B2 (el) |
KR (1) | KR100728080B1 (el) |
CN (1) | CN100450475C (el) |
AT (1) | ATE410157T1 (el) |
AU (1) | AU778360B2 (el) |
BR (1) | BR0013555A (el) |
CA (2) | CA2380673C (el) |
CY (1) | CY1109079T1 (el) |
DE (1) | DE60040487D1 (el) |
DK (1) | DK1253918T3 (el) |
ES (1) | ES2313902T3 (el) |
HK (1) | HK1051006A1 (el) |
IL (2) | IL147794A0 (el) |
MX (1) | MXPA02001587A (el) |
NO (1) | NO331307B1 (el) |
NZ (1) | NZ516767A (el) |
PT (1) | PT1253918E (el) |
WO (1) | WO2001012170A2 (el) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2804322B1 (fr) * | 2000-01-31 | 2002-04-19 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies |
US20010034373A1 (en) * | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
CN101186590A (zh) * | 2000-07-27 | 2008-05-28 | 特瓦制药工业有限公司 | 晶体和纯莫达非尼及其制备方法 |
US6919378B2 (en) * | 2000-10-11 | 2005-07-19 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
US7141555B2 (en) * | 2000-12-19 | 2006-11-28 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
US7704975B2 (en) * | 2000-12-19 | 2010-04-27 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
US7297346B2 (en) * | 2001-05-25 | 2007-11-20 | Cephalon Inc. | Pharmaceutical formulations of modafinil |
US20080058424A1 (en) * | 2002-05-23 | 2008-03-06 | Cephalon, Inc. | Novel pharmaceutical formulations of modafinil |
CN1541106A (zh) | 2001-06-11 | 2004-10-27 | 转新疗法公司 | 用维生素b12和治疗剂联合治疗病毒性、增殖性和炎性疾病的方法 |
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
US6821979B2 (en) * | 2002-03-07 | 2004-11-23 | Blanchette Rockefeller Neurosciences Institute | Synergistic enhancement of cognitive ability |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
US20040048931A1 (en) | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
US6992219B2 (en) | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
CN101606916B (zh) * | 2002-09-13 | 2011-02-09 | 赛福伦公司 | 莫达非尼片剂及其应用 |
IL153098A0 (en) * | 2002-11-26 | 2003-06-24 | Chemagis Ltd | Pharmaceutical compositions containing modafinil |
US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
AR045423A1 (es) * | 2003-05-13 | 2005-10-26 | Cephalon Inc | Combinaciones de analiticos y antidepresivos |
US8153159B2 (en) * | 2003-09-18 | 2012-04-10 | Cephalon, Inc. | Modafinil modified release pharmaceutical compositions |
US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
US20050137264A1 (en) * | 2003-12-22 | 2005-06-23 | Patel Ashish A. | Modafinil compositions |
US7314875B2 (en) * | 2004-04-13 | 2008-01-01 | Cephalon, Inc. | Tricyclic aromatic and bis-phenyl sulfinyl derivatives |
EP1586560A1 (en) * | 2004-04-13 | 2005-10-19 | Cephalon, Inc. | Thio-substituted arylmethanesulfinyl derivatives |
US7423176B2 (en) * | 2004-04-13 | 2008-09-09 | Cephalon, Inc. | Bicyclic aromatic sulfinyl derivatives |
US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
US7297817B2 (en) * | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
US7449481B2 (en) * | 2004-04-13 | 2008-11-11 | Cephalon, Inc. | Thio-substituted biaryl-methanesulfinyl derivatives |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
CA2575790A1 (en) * | 2004-09-24 | 2006-03-30 | Centre For Addiction And Mental Health | The use of a modafinil compound for the treatment of problem gambling |
US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
WO2007048803A1 (en) | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
CA2641917A1 (en) * | 2006-02-18 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin |
HUE026156T2 (en) * | 2006-05-09 | 2016-06-28 | Sprout Pharmaceuticals Inc | The use of Flibanserin for the treatment of sexual desire after menopause |
WO2008000760A1 (en) * | 2006-06-30 | 2008-01-03 | Boehringer Ingelheim International Gmbh | Flibanserin for the treatment of urinary incontinence and related diseases |
TW200820992A (en) * | 2006-07-12 | 2008-05-16 | Elan Corp Plc | Nanoparticulate formulations of modafinil |
JP2009543839A (ja) * | 2006-07-14 | 2009-12-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 女性の性的障害を治療するためのフリバンセリンの使用 |
FR2903904A1 (fr) * | 2006-07-21 | 2008-01-25 | Bioprojet Soc Civ Ile | Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 |
CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
BRPI0716439B8 (pt) | 2006-08-14 | 2021-05-25 | Boehringer Ingelheim Int | sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos |
BRPI0716436B8 (pt) * | 2006-08-25 | 2021-05-25 | Boehringer Ingelheim Int | sistema de liberação controlada e método para fabricação do mesmo |
US20080181966A1 (en) * | 2006-10-18 | 2008-07-31 | Cephalon, Inc. | Modafinil pharmaceutical compositions |
US20100010092A1 (en) * | 2006-12-19 | 2010-01-14 | Arless Ltd. | Use of modafinil to treat restless leg syndrome |
WO2008090742A1 (ja) * | 2007-01-23 | 2008-07-31 | National University Corporation Hokkaido University | 眼疾患モデル用非ヒト動物 |
US9289403B2 (en) * | 2007-03-09 | 2016-03-22 | The Board of Trustees of the University of Arizona | Use of modafinil to treat spasticity |
UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
US20090082462A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched armodafinil |
EP2238973A1 (en) | 2009-04-07 | 2010-10-13 | Cephalon France | Lyophilized preparations of proteasome inhibitors |
FR2970711B1 (fr) | 2011-01-20 | 2016-03-04 | Hopitaux Paris Assist Publique | La lauflumide et ses enantiomeres, preparation et utilisations therapeutiques |
US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
KR102150417B1 (ko) * | 2018-08-29 | 2020-09-01 | 경북대학교 산학협력단 | 복외측전시각영역 내 성상세포의 광유전학적 자극을 통한 수면 유도 동물 모델 및 이를 이용한 수면 제어제의 스크리닝 방법 |
GB201821066D0 (en) * | 2018-12-21 | 2019-02-06 | Univ Oxford Innovation Ltd | Sleep modulation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1584462A (en) | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
FR2593809B1 (fr) | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
FR2663225B1 (fr) | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
FR2697162B1 (fr) * | 1992-10-23 | 1995-01-13 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux. |
FR2707637B1 (fr) | 1993-06-30 | 1995-10-06 | Lafon Labor | Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique. |
US5618845A (en) | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
FR2771004B1 (fr) | 1997-11-19 | 2000-02-18 | Inst Curie | Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse |
WO2000050020A2 (en) * | 1999-02-24 | 2000-08-31 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
-
2000
- 2000-08-15 US US09/638,353 patent/US6346548B1/en not_active Expired - Lifetime
- 2000-08-16 CN CNB008111820A patent/CN100450475C/zh not_active Expired - Fee Related
- 2000-08-16 MX MXPA02001587A patent/MXPA02001587A/es active IP Right Grant
- 2000-08-16 KR KR1020027001958A patent/KR100728080B1/ko not_active IP Right Cessation
- 2000-08-16 ES ES00954081T patent/ES2313902T3/es not_active Expired - Lifetime
- 2000-08-16 EP EP00954081A patent/EP1253918B1/en not_active Expired - Lifetime
- 2000-08-16 AU AU66424/00A patent/AU778360B2/en not_active Ceased
- 2000-08-16 CA CA2380673A patent/CA2380673C/en not_active Expired - Fee Related
- 2000-08-16 IL IL14779400A patent/IL147794A0/xx active IP Right Grant
- 2000-08-16 AT AT00954081T patent/ATE410157T1/de active
- 2000-08-16 CA CA002689735A patent/CA2689735A1/en not_active Abandoned
- 2000-08-16 WO PCT/US2000/022338 patent/WO2001012170A2/en active IP Right Grant
- 2000-08-16 DK DK00954081T patent/DK1253918T3/da active
- 2000-08-16 NZ NZ516767A patent/NZ516767A/en not_active IP Right Cessation
- 2000-08-16 BR BRPI0013555-0A patent/BR0013555A/pt not_active Application Discontinuation
- 2000-08-16 DE DE60040487T patent/DE60040487D1/de not_active Expired - Lifetime
- 2000-08-16 JP JP2001516516A patent/JP5542291B2/ja not_active Expired - Lifetime
- 2000-08-16 PT PT00954081T patent/PT1253918E/pt unknown
-
2001
- 2001-12-20 US US10/029,306 patent/US6488164B2/en not_active Expired - Lifetime
-
2002
- 2002-01-23 IL IL147794A patent/IL147794A/en not_active IP Right Cessation
- 2002-02-15 NO NO20020772A patent/NO331307B1/no not_active IP Right Cessation
- 2002-10-30 US US10/283,573 patent/US7087647B2/en not_active Expired - Fee Related
-
2003
- 2003-05-06 HK HK03103227.6A patent/HK1051006A1/xx not_active IP Right Cessation
-
2008
- 2008-12-22 CY CY20081101486T patent/CY1109079T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109079T1 (el) | Συνθεσεις που περιλαμβανουν μονταφινιλη για την θεραπεια διαταραχης ελλειψης προσοχης υπερδραστικοτητας | |
CA2165824A1 (fr) | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet sur les apnees du sommeil et les troubles ventilatoires d'origine centrale | |
NZ502527A (en) | Catalytic monoclonal antibodies raised to proteins in aggregated form, and use to treat alzheimers, atherosclerosis, amyloidosis and prions disease | |
ATE364618T1 (de) | Antikörper gegen das muc18-antigen | |
ATE381935T1 (de) | Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen | |
MXPA05010035A (es) | Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21. | |
HUP0102511A2 (hu) | Kombinált gyógykezelés bipoláris betegségek kezelésére | |
DE60333857D1 (de) | Oxytocin zur Behandlung von Autismus und Asperger-Syndrom | |
NO975198D0 (no) | Tetralinforbindeler med MDR-aktivitet | |
WO1999060021A3 (en) | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system | |
Panta | The possible role of meditation in myofascial pain syndrome: a new hypothesis | |
SE9701161D0 (sv) | New use I | |
BR9808100A (pt) | Utilização de amandantina para tratamento de hepatite c. | |
DK0909556T3 (da) | Rosaceae-ekstrakt som bradykininantagonist | |
BR0317586A (pt) | Compostos para normalização do ciclo sono/vigìlia | |
MY126607A (en) | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue | |
MXPA04010816A (es) | Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares. | |
BR9911897B1 (pt) | composição de perfume, produto desodorante, e, processo de cosmético para a redução ou prevenção do mau cheiro do corpo. | |
ATE222768T1 (de) | Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen | |
DE60135843D1 (de) | Prävention und behandlung von mycoplasma-assoziierten krankheiten mit trans-sialidase und/oder neuraminidase | |
ATE369143T1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
MXPA05012696A (es) | Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica. | |
Kashaninasab et al. | The Quality of Sleep and Quality of Life in Patients with Alopecia | |
EP0745597A3 (en) | Novel melatonergic indanyl piperazines or homopiperazines | |
Sangolkar et al. | Schizophrenia in a case of alopecia universalis |